These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1452462)

  • 41. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
    Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
    Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
    Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
    Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
    Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of the cytostatic drugs used in the CMF-regimen.
    Slee PH; de Bruijn EA; Driessen OM; Hermans J; van Oosterom AT
    Anticancer Res; 1983; 3(4):269-71. PubMed ID: 6688337
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
    Poon MA; O'Connell MJ; Moertel CG; Wieand HS; Cullinan SA; Everson LK; Krook JE; Mailliard JA; Laurie JA; Tschetter LK
    J Clin Oncol; 1989 Oct; 7(10):1407-18. PubMed ID: 2476530
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prednimustine (Sterecyt) versus cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancer.
    Yosef H; Slater A; Keen CW; Bunting JS; Hope-Stone H; Parmar H; Roberts JT; Termander B; Nilsson B
    Eur J Cancer; 1993; 29A(8):1100-5. PubMed ID: 8518020
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinomas.
    Houghton JA; Tice AJ; Houghton PJ
    Mol Pharmacol; 1982 Nov; 22(3):771-8. PubMed ID: 7155134
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
    Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
    J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CMF and MET treatment induce cognitive impairment through upregulation of IL-1α in rat brain.
    Alhowail AH; Almogbel YS; Abdellatif AAH; Alsalehi NF; Alghenaim FA; Aldubayan MA; Felemban SG
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4385-4393. PubMed ID: 34227073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
    Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mitoxantrone, 5-fluorouracil and high-dose leucovorin (NFL) in the treatment of metastatic breast cancer: randomized comparison to cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and attempts to improve efficacy by adding paclitaxel.
    Hainsworth JD
    Eur J Cancer Care (Engl); 1997 Dec; 6(4 Suppl):4-9. PubMed ID: 9460336
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Experimental toxicologic and therapeutic studies on the activity of the CMF(cyclophosphamide-methotrexate-5-fluorouracil) scheme versus the VMF(vincristine-methotrexate-5-fluorouracil) scheme].
    Berger MR; Habs M; Schmähl D
    Arch Geschwulstforsch; 1984; 54(4):263-78. PubMed ID: 6548622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical studies of biochemical modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer by the North Central Cancer Treatment Group and Mayo Clinic.
    O'Connell MJ; Klaassen DJ; Everson LK; Cullinan S; Wieand HS
    NCI Monogr; 1987; (5):185-8. PubMed ID: 3501540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.
    Jodrell DI; Smith IE; Mansi JL; Pearson MC; Walsh G; Ashley S; Sinnett HD; McKinna JA
    Br J Cancer; 1991 May; 63(5):794-8. PubMed ID: 2039705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
    Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
    J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
    [TBL] [Abstract][Full Text] [Related]  

  • 57. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808).
    Engelsman E; Klijn JC; Rubens RD; Wildiers J; Beex LV; Nooij MA; Rotmensz N; Sylvester R
    Eur J Cancer; 1991; 27(8):966-70. PubMed ID: 1832904
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
    Smith IE; Powles TJ
    Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.
    O'Byrne KJ; Koukourakis MI; Saunders MP; Salisbury AJ; Isaacs R; Varcoe S; Taylor M; Ganesan TS; Harris AL; Talbot DC
    Br J Cancer; 1998 Jun; 77(11):1950-6. PubMed ID: 9667673
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines.
    Tsai CM; Gazdar AF; Perng RP; Kramer BS
    Int J Cancer; 1991 Feb; 47(3):401-7. PubMed ID: 1847123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.